{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:56:28Z","timestamp":1773230188604,"version":"3.50.1"},"reference-count":32,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,19]]},"DOI":"10.31744\/einstein_journal\/2023ao0486","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:55:04Z","timestamp":1703076904000},"source":"Crossref","is-referenced-by-count":2,"title":["Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen"],"prefix":"10.31744","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6056-9173","authenticated-orcid":false,"given":"Fl\u00e1via Vi\u00e9cili","family":"Tarcha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-7367","authenticated-orcid":false,"given":"Ana Lu\u00edsa de Castro","family":"Baccarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7101-4325","authenticated-orcid":false,"given":"Lilian Arruda do R\u00eago","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-3050","authenticated-orcid":false,"given":"Erika Bushatsky Andrade de","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-824X","authenticated-orcid":false,"given":"Auro","family":"del Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-4850","authenticated-orcid":false,"given":"Felipe Jos\u00e9 Silva Melo","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"key":"key20231220080845_B1","doi-asserted-by":"crossref","DOI":"10.4172\/2329-6771.1000195","article-title":"Febrile neutropenia risk with adjuvant TC (docetaxel and cyclophosphamide) regimen: experience of Brazilian cancer centers","volume":"6","author":"Gagliato","year":"2017","unstructured":". Gagliato DM, Cosseti R, Santos JP. Febrile neutropenia risk with adjuvant TC (docetaxel and cyclophosphamide) regimen: experience of Brazilian cancer centers. J Integr Oncol. 2017;6:3.","journal-title":"J Integr Oncol"},{"issue":"5","key":"key20231220080845_B2","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.13125","article-title":"Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia","volume":"28","author":"Tervonen","year":"2019","unstructured":". Tervonen HE, Chen TY, Lin E, Boyle FM, Moylan EJ, Della-Fiorentina SA, et al. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia. Eur J Cancer Care (Engl). 2019;28(5):e13125.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"9472","key":"key20231220080845_B3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":". Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.","journal-title":"Lancet"},{"issue":"2","key":"key20231220080845_B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","unstructured":". Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF,  et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-21.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20231220080845_B5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","unstructured":". Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-29.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20231220080845_B6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/tbj.13306","article-title":"Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer","volume":"25","author":"Joris","year":"2019","unstructured":". Joris S, Fontaine C, Decoster L, Vanacker L, Schallier D, De Gr\u00e8ve J. Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer. Breast J. 2019;25(4):663-6.","journal-title":"Breast J"},{"issue":"28","key":"key20231220080845_B7","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","unstructured":". Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-212. Review.","journal-title":"J Clin Oncol"},{"issue":"1","key":"key20231220080845_B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-018-5055-9","article-title":"Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials","volume":"174","author":"Caparica","year":"2019","unstructured":". Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174(1):27-37.","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"key20231220080845_B9","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","unstructured":". Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7. Erratum in: J Clin Oncol. 2007;25(13):1819.","journal-title":"J Clin Oncol"},{"issue":"8","key":"key20231220080845_B10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735","volume":"27","author":"Jones","year":"2009","unstructured":". Jones S, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177-83.","journal-title":"J Clin Oncol"},{"issue":"5","key":"key20231220080845_B11","first-page":"835","article-title":"Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer","volume":"37","author":"Kawabata","year":"2010","unstructured":". Kawabata H, Iwatani T, Makuuchi R, Miura D, Suzuki N, Nakazawa H. [Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer]. Gan To Kagaku Ryoho. 2010;37(5):835-9. Japanese.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"6","key":"key20231220080845_B12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ajco.12682","article-title":"Toxicity profile differences of adjuvant docetaxel\/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients","volume":"13","author":"Chow","year":"2017","unstructured":". Chow LW, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, et al. Toxicity profile differences of adjuvant docetaxel\/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol. 2017;13(6):372-8.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"26","key":"key20231220080845_B13","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1200\/JCO.2009.23.0508","article-title":"High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide","volume":"27","author":"Soong","year":"2009","unstructured":". Soong D, Haj R, Leung MG, Myers R, Higgins B, Myers J, et al. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol. 2009;27(26):e101-2.","journal-title":"J Clin Oncol"},{"issue":"4","key":"key20231220080845_B14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","article-title":"Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy","volume":"23","author":"Kosaka","year":"2015","unstructured":". Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer. 2015;23(4):1137-43.","journal-title":"Support Care Cancer"},{"issue":"6","key":"key20231220080845_B15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3747\/co.19.1174","article-title":"Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis","volume":"19","author":"Younus","year":"2012","unstructured":". Younus J, Vandenberg T, Jawaid M, Jawaid MA. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis. Curr Oncol. 2012;19(6):332-4.","journal-title":"Curr Oncol"},{"issue":"12","key":"key20231220080845_B16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMct1210890","article-title":"Colony-stimulating factors for febrile neutropenia during cancer therapy","volume":"368","author":"Bennett","year":"2013","unstructured":". Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368(12):1131-9. Erratum in: N Engl J Med. 2013;369(3):293. Dosage error in article text. Review.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20231220080845_B17","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s00520-020-05868-1","article-title":"Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer","volume":"29","author":"Kimura","year":"2021","unstructured":". Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer. Support Care Cancer. 2021;29(7):3507-12.","journal-title":"Support Care Cancer"},{"issue":"1","key":"key20231220080845_B18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)","volume":"89","author":"Lambertini","year":"2014","unstructured":". Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89(1):112-28.","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20231220080845_B19","author":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (CNITSUS)","year":"2022","unstructured":". Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (CNITSUS). Relat\u00f3rio de Recomenda\u00e7\u00e3o para a incorpora\u00e7\u00e3o de tecnologia no tratamento do carcinoma de mama. Bras\u00edlia (DF): CNITSUS; 2022 [citado 2023 Jun 28]. Dispon\u00edvel em: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/consultas\/relatorios\/2022\/20220919_rrcarcinoma_mama.pdf","journal-title":"Relat\u00f3rio de Recomenda\u00e7\u00e3o para a incorpora\u00e7\u00e3o de tecnologia no tratamento do carcinoma de mama"},{"issue":"11","key":"key20231220080845_B20","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(16)30384-9","article-title":"Generic oncology drugs: are they all safe?","volume":"17","author":"Yang","year":"2016","unstructured":". Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, et al. Generic oncology drugs: are they all safe? Lancet Oncol. 2016;17(11):e493-501.","journal-title":"Lancet Oncol"},{"key":"key20231220080845_B21","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications","volume":"21","author":"Crawford","year":"2010","unstructured":". Crawford J, Caserta C, Roila F; ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248-51.","journal-title":"Ann Oncol"},{"issue":"2","key":"key20231220080845_B22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molonc.2012.03.001","article-title":"Hematopoietic growth factors: personalization of risks and benefits","volume":"6","author":"Puhalla","year":"2012","unstructured":". Puhalla S, Bhattacharya S, Davidson NE. Hematopoietic growth factors: personalization of risks and benefits. Mol Oncol. 2012;6(2):237-41.","journal-title":"Mol Oncol"},{"issue":"8","key":"key20231220080845_B23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1177\/10781552211030974","article-title":"Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer","volume":"28","author":"Zekri","year":"2022","unstructured":". Zekri J, Nawaz A, Rasool H, Ahmad I, Abdel Rahman H, Dada R, et al. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer. J Oncol Pharm Pract. 2022;28(8):1681-6.","journal-title":"J Oncol Pharm Pract"},{"key":"key20231220080845_B24","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients","volume":"10","author":"Renner","year":"2012","unstructured":". Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012;10:CD007913.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"key20231220080845_B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","unstructured":". Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190-9. Review.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"key20231220080845_B26","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/ajhp\/59.suppl_4.S16","article-title":"Identification of cancer patients at high risk of febrile neutropenia","volume":"59","author":"Scott","year":"2002","unstructured":". Scott S. Identification of cancer patients at high risk of febrile neutropenia. Am J Health Syst Pharm. 2002;59(15 Suppl 4):S16-9.","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"key20231220080845_B27","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/03007995.2021.1929895","article-title":"Differences between the quality aspects of various generic and branded docetaxel formulations","volume":"37","author":"Yiding","year":"2021","unstructured":". Yiding C, Zhongyi H. Differences between the quality aspects of various generic and branded docetaxel formulations. Curr Med Res Opin. 2021;37(8):1421-33.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"key20231220080845_B28","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2351-x","article-title":"Toxicities of docetaxel: original drug versus generics-a comparative study about 81 cases","volume":"5","author":"Elm\u2019hadi","year":"2016","unstructured":". Elm\u2019hadi C, Tanz R, Khmamouche MR, Toreis M, Mahfoud T, Slimani KA, et al. Toxicities of docetaxel: original drug versus generics-a comparative study about 81 cases. Springerplus. 2016;5(1):732.","journal-title":"Springerplus"},{"issue":"4","key":"key20231220080845_B29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1060028013514941","article-title":"Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients","volume":"48","author":"Poirier","year":"2014","unstructured":". Poirier E, Desbiens C, Poirier B, Hogue JC, Lemieux J, Doyle C, et al. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Ann Pharmacother. 2014;48(4):447-55.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"key20231220080845_B30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jcph.803","article-title":"Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations","volume":"57","author":"Faqeer","year":"2017","unstructured":". Faqeer NA, Mashni O, Dawoud R, Rumman A, Hanoun E, Nazer L. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations. J Clin Pharmacol. 2017;57(2):275-9.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"key20231220080845_B31","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1185\/03007990802207874","article-title":"Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis","volume":"24","author":"Vial","year":"2008","unstructured":". Vial J, Cohen M, Sassiat P, Thi\u00e9baut D. Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin. 2008;24(7):2019-33.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"key20231220080845_B32","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00520-014-2499-2","article-title":"New cutaneous toxicities with generic docetaxel: are the excipients guilty?","volume":"23","author":"Garrido-Siles","year":"2015","unstructured":". Garrido-Siles M, Arenas-Villafranca JJ, P\u00e9rez-Ruiz E, de Linares Fern\u00e1ndez MF, Tortajada B, Rivas-Ruiz F, et al. New cutaneous toxicities with generic docetaxel: are the excipients guilty? Support Care Cancer. 2015;23(7):1917-23.","journal-title":"Support Care Cancer"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:09:06Z","timestamp":1703077746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/febrile-neutropenia-incidence-and-the-variable-toxicity-profile-between-brand-and-generic-docetaxel-in-the-adjuvant-treatment-of-breast-cancer-with-docetaxel-and-cyclophosphamide-regimen\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":32,"alternative-id":["10.31744\/einstein_journal\/2023AO0486"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2023ao0486","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"eAO0486"}}